GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Tony Wood | |||
| b) | Position/status | Chief Scientific Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
| b) | Nature of the transaction | Following the vesting on 18 February 2025 of 50% of an award made on 18 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Tony Wood will receive a cash payment of £247,942.28 less applicable tax withholding in respect of 17,182.417 notional Ordinary Shares. | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £14.4300 | 17,182.417 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
| Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-02-18 | |||
| f) | Place of the transaction
| N/A | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.